Merck & Co., Inc. (MRK)
| Market Cap | 246.49B |
| Revenue (ttm) | 63.17B |
| Net Income (ttm) | 12.15B |
| Shares Out | 2.53B |
| EPS (ttm) | 4.78 |
| PE Ratio | 20.39 |
| Forward PE | 10.70 |
| Dividend | $3.08 (3.16%) |
| Ex-Dividend Date | Sep 16, 2024 |
| Volume | 7,722,825 |
| Open | 96.98 |
| Previous Close | 96.54 |
| Day's Range | 96.66 - 98.84 |
| 52-Week Range | 94.48 - 134.63 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 132.08 (+35.55%) |
| Earnings Date | Oct 31, 2024 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv... [Read more]
Financial Performance
In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $132.08, which is an increase of 35.55% from the latest price.
News
Merck Announces First-Quarter 2025 Dividend
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2025 Dividend.
Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
In recent weeks, financial participants have remained pessimistic about Merck's development prospects, partly due to the nomination of Robert F. Kennedy Jr. as head of HHS. However, I believe Mr. Mark...
Merck's Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.
The company has been preparing for the 2028 expiration of its patents protecting Keytruda.
Injectable version of cancer drug Keytruda works as well as current IV form: Merck
CNBC's Angelica Peebles reports on news from Merck.
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
The news may help Merck retain sales of Keytruda, which is the world's best-selling drug.
Merck says Keytruda injection on par with approved IV version in trial
Merck said on Tuesday a study showed that its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of its treatment, likely making it even more...
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 tri...
Merck Among 10 Companies To Announce Annual Dividend Increases In Second Half Of November
This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. I expect 10 companies to announce their annual increases i...
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. De...
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Produ...
100 November Sustainable Dividend Dogs: 50 'Safer' And 2 Ideal Buys
Calvert Research and Management ranked the 100 most sustainable companies based on over 230 ESG indicators, including workplace diversity and greenhouse-gas emissions. Eight of 78 dividend-paying sust...
Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's stock is undervalued, trading at less than 4x expected 2024 revenues, despite strong revenue growth from Keytruda and other drugs. Keytruda's revenue is projected to increase by 70% from 2024 ...
Merck to Participate in the Jefferies London Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies London Healthcare Conference.
Immunology Biosimilars Market Research 2024-2030, Profiles of Key Players - F. Hoffmann-La Roche, Merck, Eli Lily,.
Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel, By...
Merck signs $3.3 bln deal for experimental cancer drug
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today...
Merck & Co., Inc. (MRK) UBS Global Healthcare Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK) UBS Global Healthcare Conference November 13, 2024 12:30 PM ET Company Participants Jannie Oosthuizen - President of Human Health of the U.S. Joerg Koglin - SVP of Clinic...
KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KOSELUGO Showed Significant and Clinically Meaningful Improvement in ORR Versus Placebo in Adults With NF1 who Have Symptomatic, Inoperable PNs.
Merck: An Undervalued Dividend Machine
Keytruda, Merck's flagship oncology drug, drives significant revenue growth, with a solid market position and patent protection ensuring continued growth. Merck is the second largest player in the onc...
Is MRK Stock Undervalued At $100?
Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It garnered $16.7 billion in revenue and adjusted earnings of $1.57 per share, compared t...
Merck to Participate in the UBS Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the UBS Global Healthcare Conference.
Top 2 pharma stocks to buy amid surge in deadly fungi
Recent data cited by Bloomberg reveals that deadly fungi, including Candida auris, have been spreading globally since the COVID-19 pandemic. Climate change has enabled many of these illness-causing ag...
Investing Groups Digest: Mag 7 In The Market Spotlight
Seeking Alpha's Investing Group leaders presented their earnings assessments from Mag 7 tech giants. Are investors missing hidden opportunities with BDCs, CEFs, mREITs, and preferreds? The case is mad...
